Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Macugen vs Sham in Diabetic Macular Edema
NCT00605280Phase 3Completed
- Sponsor
- Pfizer
- Start
- Sep 2005
- Primary completion
- Nov 2009
- Modality
- Antisense DNA, RNA Aptamers, Small Interfering RNA (siRNA)
- Countries
- 18
01
Overview
A Phase 3 trial of pegaptanib sodium in diabetic macular edema (DME), sponsored by Pfizer. Started Sep 2005; status: completed.
02
Drugs
pegaptanib sodium
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT00605280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00605280.